Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Carlos Escobar Cervantes, José Luis Merino & Vivencio Barrios. (2019) Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy 17:4, pages 319-330.
Read now
Read now
Articles from other publishers (19)
Carolin Ruoff, Herbert Schöchl, Gerhard Fritsch, Wolfgang Voelckel, Johannes Zipperle, Johannes Gratz, Felix Schmitt & Daniel Oberladstätter. (2023) DOAC plasma concentration upon hospital admission in a cohort of trauma patients. An observational real-life study. European Journal of Trauma and Emergency Surgery.
Crossref
Crossref
Emily Holthuis, Elisabeth Smits, George Spentzouris, Dominik Beier, Dirk Enders, Rosa Gini, Claudia Bartolini, Giampiero Mazzaglia, Fernie Penning-van Beest & Ron Herings. (2022) Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Case–Control Study from The Netherlands, Italy and Germany. Drugs - Real World Outcomes 9:4, pages 597-607.
Crossref
Crossref
Lai Heng Lee, Pongwut Danchaivijitr, Noppacharn Uaprasert, Harinder Gill, Dennis Lee Sacdalan, Gwo Fuang Ho, Rajiv Parakh, Paresh Pai, Jen-Kuang Lee, Nannette Rey & Alexander T. Cohen. (2022) Safe and effective treatment of venous Thromboembolism associated with Cancer: focus on direct Oral Anticoagulants in Asian patients. Experimental Hematology & Oncology 11:1.
Crossref
Crossref
Adane Teshome Kefale, Woldesellassie M. Bezabhe & Gregory M. Peterson. (2022) Oral Anticoagulant Discontinuation and Its Predictors in Patients with Atrial Fibrillation. Journal of Clinical Medicine 11:20, pages 6022.
Crossref
Crossref
Alessia Romagnoli, Fiorenzo Santoleri, Alberto Costantini & Angelora Di Risio. (2022) Adherence, persistence and switching rates of apixaban, dabigatran and rivaroxaban in non-valvular atrial fibrillation: a multicentre real-life analysis at 3 years. European Journal of Hospital Pharmacy, pages ejhpharm-2022-003338.
Crossref
Crossref
Elisabeth Smits, Felicita Andreotti, Eline Houben, Harry J. G. M. Crijns, Sylvia Haas, George Spentzouris, Tania Schink, Rosa Gini, Claudia Bartolini, Fernie Penning-van Beest & Ron Herings. (2022) Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. Drugs - Real World Outcomes 9:2, pages 199-209.
Crossref
Crossref
Balbir Singh, Paresh Pai, Harish Kumar, Sheeba George, Sandeep Mahapatra, Vineet Garg, G. N. Gupta, Kiran Makineni, Gaurav Ganeshwala, Pravin Narkhede, Syed M. H. Naqvi, Kumar Gaurav & Mohammed Y. K. Hukkeri. (2022) Expert Recommendations on the Usage of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) from India: Current Perspective and Future Direction. Cardiology and Therapy 11:1, pages 49-79.
Crossref
Crossref
Rodrigo Abensur Athanazio, José Manuel Ceresetto, Luis Javier Marfil Rivera, Gabriela Cesarman-Maus, Kenny Galvez, Marcos Arêas Marques, Aldo Hugo Tabares, Carlos Alberto Ortiz Santacruz, Fernando Costa Santini, Luis Corrales & Alexander T. Cohen. (2022) Direct Oral Anticoagulants for the Treatment of Cancer-Associated Venous Thromboembolism: A Latin American Perspective. Clinical and Applied Thrombosis/Hemostasis 28, pages 107602962210829.
Crossref
Crossref
. 2022. Genesis, Pathophysiology and Management of Venous and Lymphatic Disorders. Genesis, Pathophysiology and Management of Venous and Lymphatic Disorders
461
481
.
John K. Bartoli-Abdou, Jignesh P. Patel, Bipin Vadher, Alison Brown, Lara N. Roberts, Raj K. Patel, Roopen Arya & Vivian Auyeung. (2021) Long-term adherence to direct acting oral anticoagulants and the influence of health beliefs after switching from vitamin-K antagonists: Findings from the Switching Study. Thrombosis Research 208, pages 162-169.
Crossref
Crossref
Tsuyoshi Shiga, Toshimi Kimura, Noritoshi Fukushima, Yuji Yoshiyama, Kazunori Iwade, Fumiaki Mori, Yoichi Ajiro, Shoji Haruta, Yuichiro Yamada, Emi Sawada & Nobuhisa Hagiwara. (2021) Electronic monitoring of adherence to once‐daily and twice‐daily direct oral anticoagulants in patients with atrial fibrillation: Baseline data from the SMAAP‐AF trial. Journal of Arrhythmia 37:3, pages 616-625.
Crossref
Crossref
Daniel Dürschmied, Andreas Goette, Roland Hardt, Christoph Kleinschnitz, Wolfgang Kämmerer, Christoph Lembens, Wilhelm Schmitt & Christoph Bode. (2021) Interdisziplinäre Aspekte der oralen Antikoagulation mit NOAKs bei Vorhofflimmern. DMW - Deutsche Medizinische Wochenschrift 146:S 01, pages S2-S16.
Crossref
Crossref
Giuseppe Patti & Sylvia Haas. (2021) Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Journal of Cardiovascular Pharmacology 77:1, pages 11-21.
Crossref
Crossref
Myrthe M.A. Toorop, Nienke van Rein, Melchior C. Nierman, Helga W. Vermaas, Menno V. Huisman, Felix J.M. van der Meer, Suzanne C. Cannegieter & Willem M. Lijfering. (2020) Self‐reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants. Research and Practice in Thrombosis and Haemostasis 4:4, pages 586-593.
Crossref
Crossref
Nathan R. Hill, Belinda Sandler, Evelien Bergrath, Dušan Milenković, Ajibade O. Ashaye, Usman Farooqui & Alexander T. Cohen. (2020) A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation. Clinical and Applied Thrombosis/Hemostasis 26, pages 107602961989876.
Crossref
Crossref
Emanuel Raschi, Matteo Bianchin, Milo Gatti, Alessandro Squizzato & Fabrizio De Ponti. (2019) Comparative Effectiveness and Safety of Direct Oral Anticoagulants: Overview of Systematic Reviews. Drug Safety 42:12, pages 1409-1422.
Crossref
Crossref
Antonios Douros, Madeleine Durand, Carla M. Doyle, Sarah Yoon, Pauline Reynier & Kristian B. Filion. (2019) Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety 42:10, pages 1135-1148.
Crossref
Crossref
Willemijn J Comuth, Moniek P M de Maat, Daan van de Kerkhof, Jerzy Malczynski, Steen Husted, Steen D Kristensen & Anna-Marie B Münster. (2019) Adherence to dabigatran etexilate in atrial fibrillation patients intended to undergo electrical cardioversion. European Heart Journal - Cardiovascular Pharmacotherapy 5:2, pages 91-99.
Crossref
Crossref
Zhouling Xie, Yongbing Tian, Xiao Lv, Xuan Xiao, Meimiao Zhan, Kai Cheng, Shiyu Li & Chenzhong Liao. (2018) The selectivity and bioavailability improvement of novel oral anticoagulants: An overview. European Journal of Medicinal Chemistry 146, pages 299-317.
Crossref
Crossref